Published in Lancet Oncol on August 01, 2008
Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine (2012) 1.52
Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol (2013) 1.21
Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) (2011) 1.18
I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res (2010) 1.16
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet (2009) 1.03
Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage (2009) 1.02
Nerve growth factor links oral cancer progression, pain, and cachexia. Mol Cancer Ther (2011) 1.02
Highly skewed distribution of miRNAs and proteins between colorectal cancer cells and their exosomes following Cetuximab treatment: biomolecular, genetic and translational implications. Oncoscience (2014) 0.97
Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage (2012) 0.96
The role of cytokines in breast cancer development and progression. J Interferon Cytokine Res (2014) 0.95
Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev (2009) 0.95
Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nat Sci Sleep (2012) 0.92
Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One (2012) 0.90
Survival patterns in squamous cell carcinoma of the head and neck: pain as an independent prognostic factor for survival. J Pain (2014) 0.88
Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support Care Cancer (2013) 0.85
Cytokine gene associations with self-report ratings of morning and evening fatigue in oncology patients and their family caregivers. Biol Res Nurs (2014) 0.85
Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist (2011) 0.85
Biomarkers: symptoms, survivorship, and quality of life. Semin Oncol Nurs (2012) 0.85
Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs (2011) 0.83
A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv (2011) 0.82
Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer. Support Care Cancer (2013) 0.82
Personality and the risk of cancer: a 16-year follow-up study of the GAZEL cohort. Psychosom Med (2013) 0.81
Informative gene network for chemotherapy-induced peripheral neuropathy. BioData Min (2015) 0.80
Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress. Iran J Med Sci (2011) 0.80
Depressive symptoms among cancer patients in a Philippine tertiary hospital: prevalence, factors, and influence on health-related quality of life. J Palliat Med (2013) 0.80
Weight Loss, Diabetes, Fatigue, and Depression Preceding Pancreatic Cancer. Pancreas (2016) 0.78
A Polymorphic Variant of AFAP-110 Enhances cSrc Activity. Transl Oncol (2010) 0.78
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br J Cancer (2017) 0.75
Fatigue in lung cancer patients: symptom burden and management of challenges. Lung Cancer (Auckl) (2016) 0.75
The Prescription Pattern of Chinese Herbal Products Containing Ginseng among Tamoxifen-Treated Female Breast Cancer Survivors in Taiwan: A Population-Based Study. Evid Based Complement Alternat Med (2015) 0.75
Systems Chronotherapeutics. Pharmacol Rev (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Replicating genotype-phenotype associations. Nature (2007) 16.11
The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care (1991) 7.28
Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer (2000) 7.25
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A (1997) 6.99
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest (1998) 6.76
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer (1994) 5.63
Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer (1990) 5.34
Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev (1998) 3.66
The genetics of depression: a review. Biol Psychiatry (2005) 3.35
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. Lancet (2002) 3.30
Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem (2000) 3.03
The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun (2001) 2.89
Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci (2001) 2.79
Development of a symptom distress scale. Cancer Nurs (1978) 2.78
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res (2006) 2.69
The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol (1997) 2.68
The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry (2004) 2.62
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 2.49
The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun (2006) 2.40
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet (2006) 2.22
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Assessment and management of cancer-related fatigue in adults. Lancet (2003) 2.01
The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain (2005) 2.00
The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci U S A (1999) 1.96
Differential expression patterns of cytokines in complex regional pain syndrome. Pain (2007) 1.91
Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med (2005) 1.86
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res (2005) 1.84
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand (2004) 1.77
The role of cytokines in cancer-related fatigue. Cancer (2001) 1.75
Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry (1999) 1.74
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther (2007) 1.72
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 1.72
National Institutes of Health State-of-the-Science Conference Statement: Symptom management in cancer: pain, depression, and fatigue, July 15-17, 2002. J Natl Cancer Inst Monogr (2004) 1.70
Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain (2005) 1.66
Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain (2006) 1.66
Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum (2006) 1.64
Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation (2001) 1.62
Psychiatric disorders in advanced cancer. Cancer (2007) 1.50
Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J Neurochem (2006) 1.48
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
Differential expression of cytokines in painful and painless neuropathies. Neurology (2007) 1.38
Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J (2002) 1.34
Immune activation and depression in women with rheumatoid arthritis. J Rheumatol (2004) 1.34
An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res (2004) 1.30
Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol (2005) 1.28
Pain, depression, and fatigue in community-dwelling adults with and without a history of cancer. J Pain Symptom Manage (2006) 1.25
Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav Brain Res (2005) 1.25
Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behav Immun (2003) 1.24
Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol (2006) 1.20
Symptom control in palliative care--Part I: oncology as a paradigmatic example. J Palliat Med (2006) 1.08
Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet (2003) 1.07
Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev (2007) 1.05
A first study of cytokine genomic polymorphisms in CFS: Positive association of TNF-857 and IFNgamma 874 rare alleles. Clin Exp Rheumatol (2006) 1.03
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol (2006) 1.01
Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2004) 0.95
Modulation of ultraviolet-induced hyperalgesia and cytokine upregulation by interleukins 10 and 13. Br J Pharmacol (2000) 0.93
Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist. Neurosci Lett (2006) 0.92
Cytokine deregulation in cancer. Biomed Pharmacother (2001) 0.92
Increased responsiveness of rat dorsal horn neurons in vivo following prolonged intrathecal exposure to interferon-gamma. Neuroscience (2005) 0.92
Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) (2005) 0.92
Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med (2004) 0.90
Interferon-gamma induced disruption of GABAergic inhibition in the spinal dorsal horn in vivo. Pain (2007) 0.88
Cytokine polymorphism and its possible impact on cancer. Immunol Res (2004) 0.85
Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J Atheroscler Thromb (2001) 0.83
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet (2011) 9.49
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet (2008) 5.43
Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol (2013) 5.07
Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain (2006) 4.96
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Availability and integration of palliative care at US cancer centers. JAMA (2010) 4.51
Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res (2004) 4.48
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
A risk model for prediction of lung cancer. J Natl Cancer Inst (2007) 4.25
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Ignoring linkage disequilibrium among tightly linked markers induces false-positive evidence of linkage for affected sib pair analysis. Am J Hum Genet (2004) 3.83
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst (2008) 3.67
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol (2009) 3.36
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
The landscape of recombination in African Americans. Nature (2011) 3.06
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Stressing harms of physical inactivity to promote exercise. Lancet (2012) 2.93
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation (2005) 2.77
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet (2010) 2.67
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Focus on bladder cancer. Cancer Cell (2004) 2.59
Supportive versus palliative care: what's in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer (2009) 2.58
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res (2008) 2.37
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst (2008) 2.17
Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am J Epidemiol (2012) 2.16
Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16
Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer (2011) 2.15
Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst (2008) 2.15
Dehydration in cancer patients: to treat or not to treat. J Support Oncol (2004) 2.15
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res (2008) 2.11
Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev (2003) 2.09
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol (2012) 2.09
An expanded risk prediction model for lung cancer. Cancer Prev Res (Phila) (2008) 2.05
Dietary phytoestrogens and lung cancer risk. JAMA (2005) 2.04
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med (2013) 2.00
Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. Clin Cancer Res (2005) 1.98
Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer (2010) 1.97
Genome-wide association study of glioma and meta-analysis. Hum Genet (2012) 1.96
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Delirium in advanced cancer patients. Palliat Med (2004) 1.92
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) (2011) 1.86
Ask-Advise-Connect: a new approach to smoking treatment delivery in health care settings. JAMA Intern Med (2013) 1.86
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet (2011) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med (2008) 1.76
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol (2006) 1.72
"Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev (2013) 1.72
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 1.72
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine (2004) 1.70
Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet (2004) 1.70
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Re: short telomere length, cancer survival, and cancer risk in 47 102 individuals. J Natl Cancer Inst (2013) 1.69
Sarcoidosis and malignancy. Clin Dermatol (2007) 1.67